Abstract
Unbiased data-driven omic approaches are revealing the molecular heterogeneity of Alzheimer disease. Here, we used machine learning approaches to integrate high-throughput bulk and single-nucleus transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical and neuropathological data from multiple AD cohorts. We discovered four unique multimodal molecular profiles, one showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles. This profile shows similar cellular and molecular profiles in multiple affected cortical regions associated with higher Braak tau scores and significant dysregulation of synapse-related genes and endocytosis, phagosome, mTOR signaling pathways altered in AD early and late stages. The multimodal clusters uncovered cerebrospinal fluid biomarkers to monitor AD progression. AD cross-omics data integration with transcriptomic data from an SNCA mouse model revealed an overlapping signature. Our cross-omics analyses provide novel critical molecular insights into AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this work was supported by the Knight Alzheimer Disease Research Center at Washington University School of Medicine through the National Institute on Aging (NIA: grant no. P30 AG066444 - JCM), Healthy Aging and Senile Dementia (HASD: grant no. P01AG003991 - JCM), and Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study (ACS: grant no. P01AG026276 - JCM). This work was supported by grants from the National Institutes of Health: R01AG057777 (OH), K01AG046374 (CMK), R56AG067764 (OH), R01NS118146 (BAB), R21NS127211 (BAB), RF1AG071706 (BAB), and K25AG083057 (AME) and by the Chan Zuckerberg Initiative (CMK). O.H. is an Archer Foundation Research Scientist. A.M.E. is a scholar recipient of the Knight ADRC Research Education Component (NIA: grant no. P30 AG066444). This work was also supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. ROSMAP (RNA-seq) Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu. Study data were provided through NIA grant 3R01AG046171-02S2 awarded to Rima Kaddurah-Daouk at Duke University, based on specimens provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, where data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. Alzheimer's Disease Metabolomics Consortium (ADMC) The results published here are in whole or partly based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). Metabolomics data is provided by the Alzheimer's Disease Metabolomics Consortium (ADMC) and funded wholly or in part by the following grants and supplements: NIA R01AG046171, RF1AG051550, 3U01AG024904-09S4, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744, and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the ADMC, not listed specifically in this publication's author's list, provided data along with its pre-processing and prepared it for analysis but did not participate in the analysis or writing of this manuscript. A complete listing of ADMC investigators can be found at: https://sites.duke.edu/adnimetab/team/. MSBB The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). These data were generated from postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank and were provided by Dr. Eric Schadt from Mount Sinai School of Medicine. Proteomics data were provided by Dr. Levey from Emory University based on postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank provided by Dr. Eric Schadt from Mount Sinai School of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available human data from the Knight ADRC located at the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) (https://www.niagads.org/datasets) as well as data from other studies located at the AD Knowledge Portal (https://adknowledgeportal.synapse.org/). Frozen postmortem parietal lobe tissue samples from Knight Alzheimer Disease Research Center (Knight ADRC) participants, collected with informed consent for research use, were provided by the Knight ADRC Neuropathology Core. Analysis of these samples was approved by the institutional review board of Washington University in St. Louis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have extended the manuscript to include data that support the replication of our findings (Section: Knight-C4 profile is replicated consistently across multiple independent cohorts and brain regions). In addition, we have added a new section (Cross-omics integration identified CSF synaptic biomarkers for the molecular staging of AD) to show the capability of cross-omics integration as a powerful resource that provides molecular insight into the AD pathogenesis and identifies possible biomarkers for early synaptic dysfunction, cognition, and AD staging, which reflects the novelty of this study.
Data availability
Transcriptomics data from the Knight ADRC are available by request from the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) with accession number ng00083 (https://www.niagads.org/datasets/ng00083). Proteomics data from the Knight ADRC donors are available at the NIAGADS Knight ADRC collection with accession number ng00102 (https://www.niagads.org/datasets/ng00102). Metabolomics data from the Knight ADRC are available at the NIAGADS Knight ADRC collection with accession number NG00113 (https://dss.niagads.org/datasets/ng00113/). The single nucleus data from the Knight ADRC are available at NIAGADS Knight ADRC collection with accession number NG00108 (https://dss.niagads.org/datasets/ng00108/). MSBB transcriptomics and proteomics data are publicly available at Synapse under Synapse IDs syn3157743 (https://www.synapse.org/#!Synapse:syn3157743) and syn25006650 (https://www.synapse.org/#!Synapse:syn25006650) respectively. ROSMAP transcriptomics and metabolomics data are publicly available at Synapse under Synapse IDs syn17008934 (https://www.synapse.org/#!Synapse:syn17008934) and syn25878459 (https://www.synapse.org/#!Synapse:syn25878459) respectively.
